Relay Therapeutics (RLAY) announces acquisition of ZebiAI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI
April 16, 2021 6:00 AM EDTRelay Therapeutics leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields
ZebiAI amplifies Relay Therapeutics Dynamo platform with a library of industry-leading experimental DEL data sets and validated machine learning models deployed in hit finding and optimization of novel medicines
Relay Therapeutics to host conference call at 8:00 a.m. ET
CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the... More
